Abstract:BackgroundMuscle-invasive bladder cancer (MIBC) accounts for approximately 20% of all urothelial bladder carcinomas (UBC) at time of diagnosis, and up to 30% of patients with non-muscle invasive UBC will progress to MIBC over time. An increasing body of evidence has revealed a strong correlation between aberrant DNA methylation and tumorigenesis in MIBC.ResultsUsing The Cancer Genome Atlas (TCGA) molecular data for 413 patients, we described a DNA methylation-based signature as a prognostic factor for overall survival (OS) in MIBC patients. By using a least absolute shrinkage and selection operator (LASSO) model, differentially methylated regions were first identified using multiple criteria followed by survival and LASSO analyses to identify DNA methylation probes related to OS and build a classifier to stratify patients with MIBC. The prognostic value of the classifier, referred to as risk score (RS), was validated in a held-out testing set from the TCGA MIBC cohort. Finally, receiver operating characteristic (ROC) analysis was used to compare the prognostic accuracy of the models built with RS alone, RS plus clinicopathologic features, and clinicopathologic features alone. We found that our seven-probe classifier-based RS stratifies patients into high- and low-risk groups for overall survival (OS) in the testing set (n = 137) (AUC at 3 years, 0.65; AUC at 5 years, 0.65). In addition, RS significantly improved the prognostic model when it was combined with clinical information including age, smoking status, Tumor (T) stage, and Lymph node metastasis (N) stage.ConclusionsThe DNA methylation-based RS can be a useful tool to predict the accuracy of preoperative and/or post-cystectomy models of OS in MIBC patients.

Additional File 2 of DNA Methylation Subtypes Guiding Prognostic Assessment and Linking to Responses the DNA Methyltransferase Inhibitor SGI-110 in Urothelial Carcinoma

DNA methylation subtypes guiding prognostic assessment and linking to responses the DNA methyltransferase inhibitor SGI-110 in urothelial carcinoma

A Novel DNA Methylation Signature As an Independent Prognostic Factor in Muscle-Invasive Bladder Cancer

Additional File 2 of Prognostic Role of METTL1 in Glioma

Additional File 1 of Genetic Alterations and Functional Networks of M6a RNA Methylation Regulators in Pancreatic Cancer Based on Data Mining

Additional File 11: Table S7. of Global Analysis of DNA Methylation in Hepatocellular Carcinoma by a Liquid Hybridization Capture-Based Bisulfite Sequencing Approach

Additional File 12: Table S11. of Identification of Prognostic Signature in Cancer Based on DNA Methylation Interaction Network

A Systematic Analysis On Dna Methylation And The Expression Of Both Mrna And Microrna In Bladder Cancer

Additional File 1 of Robust Performance of a Novel Stool DNA Test of Methylated SDC2 for Colorectal Cancer Detection: a Multicenter Clinical Study

Additional File 8: of Subtyping of Microsatellite Instability-High Colorectal Cancer

Additional File 2 of Identification and Validation of a Six-Gene Signature Associated with Glycolysis to Predict the Prognosis of Patients with Cervical Cancer

Identification of Prognostic DNA Methylation Signatures in Lung Adenocarcinoma

Additional File 7: Table S3. of Global Analysis of DNA Methylation in Hepatocellular Carcinoma by a Liquid Hybridization Capture-Based Bisulfite Sequencing Approach

Additional File 17: Table S16. of the Signature of Liver Cancer in Immune Cells DNA Methylation

Additional File 7: Table S6. of Identification of Prognostic Signature in Cancer Based on DNA Methylation Interaction Network

Additional File 2 of Genetic Alteration of Chinese Patients with Rectal Mucosal Melanoma

Additional File 16: Table S15. of the Signature of Liver Cancer in Immune Cells DNA Methylation

Additional File 2: of Mutation Status Coupled with RNA-sequencing Data Can Efficiently Identify Important Non-Significantly Mutated Genes Serving As Diagnostic Biomarkers of Endometrial Cancer

Additional File 2 of Evaluation of Acute Myeloid Leukemia Blast Percentage on MethylC-Capture Sequencing Results

Additional File 13 of Pan-cancer Analysis Revealed H3K4me1 at Bivalent Promoters Premarks DNA Hypermethylation During Tumor Development and Identified the Regulatory Role of DNA Methylation in Relation to Histone Modifications

Additional File 1 of Patient Specific Circulating Tumor DNA Fingerprints to Monitor Treatment Response Across Multiple Tumors